Structured Review

Maxxam Analytics liquid chromatography tandem mass spectrometry
Liquid Chromatography Tandem Mass Spectrometry, supplied by Maxxam Analytics, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/liquid chromatography tandem mass spectrometry/product/Maxxam Analytics
Average 92 stars, based on 1 article reviews
Price from $9.99 to $1999.99
liquid chromatography tandem mass spectrometry - by Bioz Stars, 2020-07
92/100 stars

Images

Related Articles

Chromatography:

Article Title: Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects
Article Snippet: .. Samples were prepared using solid-phase extraction and analysed using liquid chromatography/tandem mass spectrometry (Maxxam Analytics Inc., Mississauga, ON, Canada). .. Resting ECG measurements were recorded at −75 and −45 min predose and then immediately before each pharmacokinetic blood sampling after subjects had been semirecumbent for at least 30 min.

Mass Spectrometry:

Article Title: Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects
Article Snippet: .. Samples were prepared using solid-phase extraction and analysed using liquid chromatography/tandem mass spectrometry (Maxxam Analytics Inc., Mississauga, ON, Canada). .. Resting ECG measurements were recorded at −75 and −45 min predose and then immediately before each pharmacokinetic blood sampling after subjects had been semirecumbent for at least 30 min.

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92
    Maxxam Analytics maraviroc
    Mean <t>maraviroc</t> plasma concentration–time profiles for maraviroc with and without cotrimoxazole (study 1, day 7). Maraviroc 300 mg BID + co-trimoxazole 960 mg BID (▴); Maraviroc 300 mg BID + placebo (▪)
    Maraviroc, supplied by Maxxam Analytics, used in various techniques. Bioz Stars score: 92/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/maraviroc/product/Maxxam Analytics
    Average 92 stars, based on 3 article reviews
    Price from $9.99 to $1999.99
    maraviroc - by Bioz Stars, 2020-07
    92/100 stars
      Buy from Supplier

    85
    Maxxam Analytics bioanalytical lc ms based
    Mean <t>maraviroc</t> plasma concentration–time profiles for maraviroc with and without cotrimoxazole (study 1, day 7). Maraviroc 300 mg BID + co-trimoxazole 960 mg BID (▴); Maraviroc 300 mg BID + placebo (▪)
    Bioanalytical Lc Ms Based, supplied by Maxxam Analytics, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bioanalytical lc ms based/product/Maxxam Analytics
    Average 85 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bioanalytical lc ms based - by Bioz Stars, 2020-07
    85/100 stars
      Buy from Supplier

    92
    Maxxam Analytics liquid chromatography tandem mass spectrometry
    Mean <t>maraviroc</t> plasma concentration–time profiles for maraviroc with and without cotrimoxazole (study 1, day 7). Maraviroc 300 mg BID + co-trimoxazole 960 mg BID (▴); Maraviroc 300 mg BID + placebo (▪)
    Liquid Chromatography Tandem Mass Spectrometry, supplied by Maxxam Analytics, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/liquid chromatography tandem mass spectrometry/product/Maxxam Analytics
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    liquid chromatography tandem mass spectrometry - by Bioz Stars, 2020-07
    92/100 stars
      Buy from Supplier

    Image Search Results


    Mean maraviroc plasma concentration–time profiles for maraviroc with and without cotrimoxazole (study 1, day 7). Maraviroc 300 mg BID + co-trimoxazole 960 mg BID (▴); Maraviroc 300 mg BID + placebo (▪)

    Journal: British Journal of Clinical Pharmacology

    Article Title: The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers

    doi: 10.1111/j.1365-2125.2008.03135.x

    Figure Lengend Snippet: Mean maraviroc plasma concentration–time profiles for maraviroc with and without cotrimoxazole (study 1, day 7). Maraviroc 300 mg BID + co-trimoxazole 960 mg BID (▴); Maraviroc 300 mg BID + placebo (▪)

    Article Snippet: Samples were prepared using solid-phase extraction (plasma) or protein precipitation (urine) and assayed for maraviroc using liquid chromatography and tandem mass spectrometry (Maxxam Analytics Inc., Mississauga, ON, Canada).

    Techniques: Concentration Assay

    Mean maraviroc plasma concentration–time profiles for maraviroc with and without tenofovir (study 2, day 7). Maraviroc 300 mg BID + tenofovir 300 mg QD (▴); Maraviroc 300 mg BID + placebo (▪)

    Journal: British Journal of Clinical Pharmacology

    Article Title: The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers

    doi: 10.1111/j.1365-2125.2008.03135.x

    Figure Lengend Snippet: Mean maraviroc plasma concentration–time profiles for maraviroc with and without tenofovir (study 2, day 7). Maraviroc 300 mg BID + tenofovir 300 mg QD (▴); Maraviroc 300 mg BID + placebo (▪)

    Article Snippet: Samples were prepared using solid-phase extraction (plasma) or protein precipitation (urine) and assayed for maraviroc using liquid chromatography and tandem mass spectrometry (Maxxam Analytics Inc., Mississauga, ON, Canada).

    Techniques: Concentration Assay

    (A) Mean plasma concentrations of maraviroc by treatment and day (study 4). (B) Trough plasma concentrations of maraviroc by treatment (study 4). MVC, maraviroc; TPV/r, ritonavir-boosted tipranavir. MVC + TPV/r (▪); MVC + Placebo (□)

    Journal: British Journal of Clinical Pharmacology

    Article Title: Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

    doi: 10.1111/j.1365-2125.2008.03133.x

    Figure Lengend Snippet: (A) Mean plasma concentrations of maraviroc by treatment and day (study 4). (B) Trough plasma concentrations of maraviroc by treatment (study 4). MVC, maraviroc; TPV/r, ritonavir-boosted tipranavir. MVC + TPV/r (▪); MVC + Placebo (□)

    Article Snippet: Plasma samples from studies 1 and 2 were assayed for maraviroc by Maxxam Analytics Inc. (Mississauga, ON, Canada) using a previously validated liquid chromatography with tandem mass spectrometry (LC/MS/MS) method.

    Techniques:

    Schematic of study design (study 2). LPV, lopinavir; MVC, maraviroc; R, ritonavir; SQV, saquinavir

    Journal: British Journal of Clinical Pharmacology

    Article Title: Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

    doi: 10.1111/j.1365-2125.2008.03133.x

    Figure Lengend Snippet: Schematic of study design (study 2). LPV, lopinavir; MVC, maraviroc; R, ritonavir; SQV, saquinavir

    Article Snippet: Plasma samples from studies 1 and 2 were assayed for maraviroc by Maxxam Analytics Inc. (Mississauga, ON, Canada) using a previously validated liquid chromatography with tandem mass spectrometry (LC/MS/MS) method.

    Techniques:

    Mean plasma concentrations of maraviroc by treatment and day (study 3). ATZ, atazanavir; ATZ/r, ritonavir-boosted atazanavir; MVC, maraviroc. Day 7 MVC + ATZ ( ); Day 7 MVC + Placebo (▪); Day 14 MVC + ATZ/r (○); Day 14 MVC + Placebo (□)

    Journal: British Journal of Clinical Pharmacology

    Article Title: Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

    doi: 10.1111/j.1365-2125.2008.03133.x

    Figure Lengend Snippet: Mean plasma concentrations of maraviroc by treatment and day (study 3). ATZ, atazanavir; ATZ/r, ritonavir-boosted atazanavir; MVC, maraviroc. Day 7 MVC + ATZ ( ); Day 7 MVC + Placebo (▪); Day 14 MVC + ATZ/r (○); Day 14 MVC + Placebo (□)

    Article Snippet: Plasma samples from studies 1 and 2 were assayed for maraviroc by Maxxam Analytics Inc. (Mississauga, ON, Canada) using a previously validated liquid chromatography with tandem mass spectrometry (LC/MS/MS) method.

    Techniques:

    (A) Trough maraviroc plasma concentrations by treatment (study 2). (B) Mean plasma maraviroc concentrations on treatment day 21. (C) Mean plasma maraviroc concentrations on treatment day 28. LPV/r, ritonavir-boosted lopinavir; MVC, maraviroc; R, ritonavir;

    Journal: British Journal of Clinical Pharmacology

    Article Title: Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

    doi: 10.1111/j.1365-2125.2008.03133.x

    Figure Lengend Snippet: (A) Trough maraviroc plasma concentrations by treatment (study 2). (B) Mean plasma maraviroc concentrations on treatment day 21. (C) Mean plasma maraviroc concentrations on treatment day 28. LPV/r, ritonavir-boosted lopinavir; MVC, maraviroc; R, ritonavir;

    Article Snippet: Plasma samples from studies 1 and 2 were assayed for maraviroc by Maxxam Analytics Inc. (Mississauga, ON, Canada) using a previously validated liquid chromatography with tandem mass spectrometry (LC/MS/MS) method.

    Techniques:

    Mean plasma concentrations of maraviroc by treatment (day 7, study 1). K, ketoconazole; MVC, maraviroc; SQV, saquinavir. Day 7 MVC + Ketoconazole ( ); Day 7 MVC + Saquinavir (▴); Day 7 MVC + Placebo (K) (▪); Day 7 MVC + Placebo (SQV) (♦)

    Journal: British Journal of Clinical Pharmacology

    Article Title: Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

    doi: 10.1111/j.1365-2125.2008.03133.x

    Figure Lengend Snippet: Mean plasma concentrations of maraviroc by treatment (day 7, study 1). K, ketoconazole; MVC, maraviroc; SQV, saquinavir. Day 7 MVC + Ketoconazole ( ); Day 7 MVC + Saquinavir (▴); Day 7 MVC + Placebo (K) (▪); Day 7 MVC + Placebo (SQV) (♦)

    Article Snippet: Plasma samples from studies 1 and 2 were assayed for maraviroc by Maxxam Analytics Inc. (Mississauga, ON, Canada) using a previously validated liquid chromatography with tandem mass spectrometry (LC/MS/MS) method.

    Techniques: